Saskatchewan MP Corey Tocher has introduced legislation to streamline access to psilocybin-assisted therapy in Canada. The private member’s bill aims to remove bureaucratic barriers within Health Canada’s Special Access Program, empowering physicians to prescribe the treatment directly for anxiety, depression, and PTSD.
Named after Thomas Hartle, a cancer patient who utilized the therapy before his death, the bill addresses critical delays in the current approval system. Advocates argue that existing protocols force terminally ill and mentally distressed patients to navigate slow administrative processes or seek treatment abroad. Proponents emphasize that immediate access is vital for effective mental health intervention.
Clinical evidence suggests psilocybin facilitates neural pathway reorganization, offering relief where traditional pharmaceuticals fail. Veterans and mental health professionals report significant reductions in suicidal ideation and trauma-related symptoms. Supporters contend that regulatory oversight currently impedes the doctor-patient relationship and restricts a legitimate healthcare option.
The legislation remains in early parliamentary stages and requires broad political support to become law. If passed, it would mark a significant shift in Canadian drug policy, integrating psychedelic-assisted psychotherapy into mainstream medical practice alongside established end-of-life care options.